Related Experiment Video
Updated: Nov 25, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy
Bijay Singh1,2, Shicheng Yang1,3, Apurva Krishna1,4
1Nanomedicine Innovation Center, Northeastern University, Boston, MA, United States.
Abstract:
A number of poly(ADP-ribose) polymerase (PARP) inhibitors have been recently approved for clinical use in BRCA mutated and other cancers. However, off-target toxicity of PARP inhibitors and the emergence of drug resistance following prolonged administration of these inhibitors indicate the need for improved methods of drug delivery to the tumors. Nanomedicines based upon nanoparticle formulations of conventional small molecule drugs and inhibitors offer many advantages, such as increased solubility and bioavailability of drugs, reduced toxicity and drug resistance, and improved tissue selectivity and therapeutic efficacy. This review highlights the current trends in formulations of PARP inhibitors developed by nanotechnology approaches and provides an insight into the applications and limitations of these PARP inhibitor nanomedicines for cancer therapies.
Insights
Nanoparticle drug delivery systems offer improved cancer treatment by enhancing poly(ADP-ribose) polymerase (PARP) inhibitor efficacy and reducing toxicity. This nanotechnology approach addresses challenges like drug resistance and off-target effects in cancer therapy.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Poly(ADP-ribose) polymerase (PARP) inhibitors are approved for treating BRCA-mutated cancers.
- Off-target toxicity and drug resistance limit the efficacy of current PARP inhibitors.
- Improved drug delivery methods are needed to enhance tumor targeting and therapeutic outcomes.
Purpose of the Study:
- To review current nanotechnology-based formulations of PARP inhibitors.
- To explore the applications and limitations of nanomedicines for cancer therapy.
Main Methods:
- Literature review of nanotechnology approaches for PARP inhibitor formulation.
- Analysis of nanoparticle-based drug delivery systems for cancer treatment.
Main Results:
- Nanoparticle formulations enhance solubility, bioavailability, and tissue selectivity of PARP inhibitors.
- Nanomedicines can reduce off-target toxicity and overcome drug resistance.
- Current trends focus on optimizing nanocarrier systems for PARP inhibitors.
Conclusions:
- Nanotechnology offers promising strategies for developing advanced PARP inhibitor therapies.
- PARP inhibitor nanomedicines show potential for improved efficacy and reduced side effects in cancer treatment.
- Further research is needed to fully realize the clinical applications of these nanomedicines.
More Related Videos
Related Concept Videos
02:15Experimental RNAi
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...